Top

Published in:

01-11-2009 | Case Management and Clinical Consequences

Lymph node dissection in primary intrahepatic malignant mesothelioma: case report and implications for diagnosis and therapy

Authors: Bettina M. Buchholz, Ines Gütgemann, Hans-Peter Fischer, Marcus Gorschlüter, Andreas Türler, Jörg C. Kalff, Andreas Hirner, Jens Standop

Published in: Langenbeck's Archives of Surgery | Issue 6/2009

Abstract

Introduction

In this rare case of intrahepatic malignant mesothelioma with subsequent lymph node metastases, hepatic segmentectomy in combination with repeated lymphadenectomy resulted in prolonged survival, currently 37 months after initial diagnosis.

Discussion

Immunohistochemically, vascular endothelial growth factor receptor-1 expressing tumor cells were surrounded by a dense D 2–40-positive lymphangiovascular network, suggesting tumor induced lymphangiogenesis correlating to 2-deoxy-2[¹⁸F]fluoro-d-glucose-positron emission tomography/computed tomography-positive recurrent intraabdominal and intrathoracic lymphatic tumor spread. Therefore, extended lymphadenectomy during primary tumor resection and combined adjuvant chemotherapy with promising anticancer agents possessing antilymphangiogenic and antimetabolite properties should be considered to prolong survival in cases of extrathoracic malignant mesothelioma. Additionally, as shown in our case, individual operative concepts and (sometimes) multiple operations can be beneficial for highly selected patients. Importantly, a case-by-case optimized antitumor regimen requires interdisciplinary expertise and consensus of all involved faculties.

Sohrab S, Hinterthaner M, Stamatis G, Rödelsberger K, Woitowitz H-J, Konietzko N (2000) Das maligne Pleuramesotheliom. Dtsch Arztebl 97:A3257–A3262

Chabot JF, Beard D, Langlois AJ, Beard JW (1970) Mesotheliomas of peritoneum, epicardium, and pericardium induced by strain MC29 avian leukosis virus. Cancer Res 30:1287–1308PubMed

Carbone M, Pass HI (2006) Evolving aspects of mesothelioma carcinogenesis: SV40 and genetic predisposition. J Thorac Oncol 1:169–171. doi:10.1097/01243894-200602000-00012 CrossRefPubMed

Antropoli M, Freda F, Apicella A, Nunziata L, Cutolo PP, Antropoli C et al (2002) Peritoneal multicystic mesothelioma: unusual case of localization in the left lobe of the liver. Chir Ital 54:897–902PubMed

Gupta S, Gupta RK, Gujral RB, Agarwal D, Saxena R, Tandon P (1992) Peritoneal mesothelioma simulating pseudomyxoma peritonei on CT and sonography. Gastrointest Radiol 17:129–131. doi:10.1007/BF01888527 CrossRefPubMed

Horling EW, Albert C, Bassermann R, Stiegler H (1996) Multicystic peritoneal mesothelioma. Zentralbl Chir 121:587–590PubMed

Matsukuma S, Aida S, Hata Y, Sugiura Y, Tamai S (1996) Localized malignant peritoneal mesothelioma containing rhabdoid cells. Pathol Int 46:389–391. doi:10.1111/j.1440-1827.1996.tb03627.x CrossRefPubMed

Iczkowski KA, Katz G, Zander DS, Clapp WL (2002) Malignant mesothelioma of tunica vaginalis testis: a fatal case with liver metastasis. J Urol 167:645–646. doi:10.1016/S0022-5347(01) 69106-7 CrossRefPubMed

Chen KT, Arhelger RB, Flam MS, Hanson JH (1982) Malignant mesothelioma of tunica vaginalis testis. Urology 20:316–319. doi:10.1016/0090-4295(82) 90652-5 CrossRefPubMed

10.

Gütgemann I, Standop J, Fischer HP (2006) Primary intrahepatic malignant mesothelioma of epithelioid type. Virchows Arch 448:655–658. doi:10.1007/s00428-006-0175-8 CrossRefPubMed

11.

Blasi AD, Boscaino A, De Dominicis G, Marsilia GM, D’Antonio A, Nappi O (2004) Multicystic mesothelioma of the liver with secondary involvement of peritoneum and inguinal region. Int J Surg Pathol 12:87–91. doi:10.1177/106689690401200116 CrossRefPubMed

12.

Imura J, Ichikawa K, Takeda J, Iwasaki Y, Tomita S, Kubota K et al (2002) Localized malignant mesothelioma of the epithelial type occurring as a primary hepatic neoplasm: a case report with review of the literature. APMIS 110:789–794. doi:10.1034/j.1600-0463.2002.t01-1-1101102.x CrossRefPubMed

13.

Leonardou P, Semelka RC, Kanematsu M, Braga L, Woosley JT (2003) Primary malignant mesothelioma of the liver: MR imaging findings. Magn Reson Imaging 21:1091–1093. doi:10.1016/S0730-725X(03) 00197-8 CrossRefPubMed

14.

Churg A, Colby TV, Cagle P, Corson J, Gibbs AR, Gilks B et al (2000) The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 24:1183–1200. doi:10.1097/00000478-200009000-00001 CrossRefPubMed

15.

Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M (2007) VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 109:1010–1017. doi:10.1182/blood-2006-05-021758 CrossRefPubMed

16.

Skobe M, Hamberg LM, Hawighorst T, Schirner M, Wolf GL, Alitalo K et al (2001) Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 159:893–903PubMed

17.

Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M et al (1999) VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81:54–61. doi:10.1038/sj.bjc.6690650 CrossRefPubMed

18.

Plate K (2001) From angiogenesis to lymphangiogenesis. Nat Med 7:151–152. doi:10.1038/84579 CrossRefPubMed

19.

Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R et al (2001) VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7:186–191. doi:10.1038/84635 CrossRefPubMed

20.

Achen MG, McColl BK, Stacker SA (2005) Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 7:121–127. doi:10.1016/j.ccr.2005.01.017 CrossRefPubMed

21.

Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, Hirohashi S (2000) Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 6:2431–2439PubMed

22.

Skobe M, Detmar M (2000) Structure, function, and molecular control of the skin lymphatic system. J Investig Dermatol Symp Proc 5:14–19. doi:10.1046/j.1087-0024.2000.00001.x CrossRefPubMed

23.

Scavelli C, Vacca A, Di PG, Dammacco F, Ribatti D (2004) Crosstalk between angiogenesis and lymphangiogenesis in tumor progression. Leukemia 18:1054–1058. doi:10.1038/sj.leu.2403355 CrossRefPubMed

24.

Murakami M, Zheng Y, Hirashima M, Suda T, Morita Y, Ooehara J et al (2008) VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment. Arterioscler Thromb Vasc Biol 28:658–664. doi:10.1161/ATVBAHA.107.150433 CrossRefPubMed

25.

Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C et al (2004) VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 113:1040–1050PubMed

26.

Aishima S, Nishihara Y, Iguchi T, Taguchi K, Taketomi A, Maehara Y et al (2008) Lymphatic spread is related to VEGF-C expression and D2–40-positive myofibroblasts in intrahepatic cholangiocarcinoma. Mod Pathol 21:256–264. doi:10.1038/modpathol.3800985 CrossRefPubMed

27.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550. doi:10.1056/NEJMoa061884 CrossRefPubMed

28.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342. doi:10.1056/NEJMoa032691 CrossRefPubMed

29.

Li Q, Yano S, Ogino H, Wang W, Uehara H, Nishioka Y et al (2007) The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res 13:5918–5925. doi:10.1158/1078-0432.CCR-07-0501 CrossRefPubMed

30.

Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL et al (1997) LY231514, a pyrrolo[2, 3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116–1123PubMed

31.

Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, Barredo J et al (1992) A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3, 4-dihydro-4-oxo-7H-pyrrolo[2, 3-d]pyrimidin-5- yl) ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 35:4450–4454. doi:10.1021/jm00101a023 CrossRefPubMed

32.

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644. doi:10.1200/JCO.2003.11.136 CrossRefPubMed

33.

Tsiouris A, Walesby RK (2007) Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol 4:344–352. doi:10.1038/ncponc0839 CrossRefPubMed

34.

Vogelzang NJ, Porta C, Mutti L (2005) New agents in the management of advanced mesothelioma. Semin Oncol 32:336–350. doi:10.1053/j.seminoncol.2005.02.010 CrossRefPubMed

35.

Yamamuro M, Gerbaudo VH, Gill RR, Jacobson FL, Sugarbaker DJ, Hatabu H (2007) Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol 64:356–366. doi:10.1016/j.ejrad.2007.08.010 CrossRefPubMed

36.

Truong MT, Marom EM, Erasmus JJ (2006) Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging. J Thorac Imaging 21:146–153. doi:10.1097/00005382-200605000-00006 CrossRefPubMed

37.

Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S et al (2006) Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol 24:4587–4593. doi:10.1200/JCO.2006.06.8999 CrossRefPubMed

Title: Lymph node dissection in primary intrahepatic malignant mesothelioma: case report and implications for diagnosis and therapy
Authors: Bettina M. Buchholz
Ines Gütgemann
Hans-Peter Fischer
Marcus Gorschlüter
Andreas Türler
Jörg C. Kalff
Andreas Hirner
Jens Standop
Publication date: 01-11-2009
Publisher: Springer-Verlag
Published in: Langenbeck's Archives of Surgery / Issue 6/2009
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-009-0476-x

At a glance: The STEP trials

Springer Medicine

Lymph node dissection in primary intrahepatic malignant mesothelioma: case report and implications for diagnosis and therapy

Abstract

Introduction

Discussion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Discussion

Please log in to get access to this content

Other articles of this Issue 6/2009

Bridging the divide between the surgeon and the interventional radiologist: cooperation or/and competition?

Reply to Dr. Peparini’s Letter to the Editor regarding the publication titled “Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R and PDGF-R in colorectal adenocarcinomas”

Appendicitis score for children with suspected appendicitis. A randomized clinical trial

Expression of receptors tyrosine kinase c-kit and EGF-R in colorectal adenocarcinomas: is there a relationship with epithelial–mesenchymal transition during tumor progression?

Reconstruction of the portal and hepatic veins using venous grafts customized from the bilateral gonadal veins

Intraoperative application of “white test” to reduce postoperative bile leak after major liver resection: results of a prospective cohort study in 137 patients